NP-1 contains the FDA-approved drugs amitriptyline and ketamine to relieve pain from various peripheral neuropathies in chemotherapy-induced peripheral neuropathy (CPN).
The Community Clinical Oncology Program funded, multi-center, double-blind, randomized, placebo-controlled study was conducted by the National Cancer Institute (NCI).
The results of the trial demonstrated that the change in average daily neuropathy intensity scores in the NP-1 group achieved a statistically significant reduction in CPN intensity versus placebo.
EpiCept president and CEO Jack Talley said the positive results achieved by NP-1 demonstrate its potential to be a new and effective treatment option for sufferers of CPN.